Navigation Links
YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
Date:9/4/2007

zumab at three dose levels (100mg, 200mg and 400mg weekly) with palliative radiation (30 Gy in 10 fractions). The data will be used to select the optimal effective dose for the randomized Phase II component of the study, in which Overall Survival will be the primary endpoint.

Of the six patients enrolled in the 1st cohort (100mg), four Partial Response (PR) and two Stable Disease (SD) were reported as at August 14, 2007. Median Overall Survival of the group was 41.5 weeks. All patients ultimately progressed. Two severe adverse events have been reported, neither causally attributable to nimotuzumab. A notable absence of grade III/IV rash or diarrhea in this cohort was reported.

Of the seven patients enrolled in the 2nd cohort (200mg) of the study, two PR and five SD were reported as at August 14, 2007 Median overall survival of the group has not been reached but currently exceeds 25 weeks. There has been a notable absence of grade III/IV rash or diarrhea reported in this cohort.

Enrolment is now ongoing into the third cohort, to be treated at 400 mg per dose level, and accrual is anticipated to be completed by the end of 2007.

YM is conducting the trial in Canada and Kuhnil Pharmaceutical Co. is conducting a parallel trial in Korea with a common protocol. This structure is designed to accelerate overall recruitment and lower the costs to the participants. The interim report from Phase I Korean patients is anticipated early in 2008.

The poster presentation is entitled "Preliminary Results Of An Escalating Dose (Phase I /II Clinical) Trial Of The Anti EGFR Monoclonal Antibody Nimotuzumab In Combination With External Radiotherapy In Patients Diagnosed With Stage IIB, III or IV NSCLC Unsuitable For Radical Therapy" by Gwyn Bebb, Colum Smith, Anthony Brade, Stewart Rorke and Igor Sherman. The poster, P3 - 023, will be on display on September 5 & 6 at Atlantic Halls 5 - 8 in poster session 3 - Novel Therapeutics: Molecular Therapeutics.


'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... today declared a $0.61 per share dividend for the ... on Sept. 5, 2014, to all stockholders of record ... 2014.  About Amgen Amgen is committed ... from serious illnesses by discovering, developing, manufacturing and delivering ...
(Date:7/25/2014)... -- Trillions of bacteria live in each person,s digestive ... digest food and stave off harmful infections, but their ... To help shed light on the role of these ... professor Eric Alm recently tracked fluctuations in the bacterial ... The findings, described in the July 25 issue of ...
(Date:7/25/2014)... the University of Leicester has furthered our understanding ... to create new materials using nanosized ,building blocks,. ... the prestigious academic journal Physical Review Letters ... in rich detail the structure and internal atomic ... molecule and a single helium atom. , The ...
(Date:7/25/2014)... DUBLIN , July 25, 2014 ... of the "Global Metabolomics Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics ... metabolites. Metabolomics has become a new experimental technique ... and the environmental sciences. Metabolites are small molecules ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2
... Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/,-- Evotec ... it has,successfully completed a Phase I safety and ... the good tolerability profile of EVT,302 and are ... EVT 302, a reversible and highly selective inhibitor ...
... SANTA MONICA, Calif., Jan. 7 Aida,Pharmaceuticals, Inc. ... received an award from the Science and Technology ... in China and known throughout,the country for its ... authority because of its "clinical research and,commercialization of ...
... from the department of macromolecular science and engineering ... Cleveland VA Medical Center and the NASA Glenn ... Nature Nanotechnology, one of the worlds most prestigious ... Jeffrey R. Capadona, associate investigator at the VAs ...
Cached Biology Technology:Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 2Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 3Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 4Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 5Aida Receives Chinese Government Innovation Award 2
(Date:7/25/2014)... N.Y., July 25, 2014 In the first broad-scale estimate ... Service scientists and collaborators calculated that trees are saving ... 670,000 incidences of acute respiratory symptoms. , While trees, ... of less than 1 percent, the impacts of that ... of the reduced air pollution at nearly $7 billion ...
(Date:7/25/2014)... colonial era, 100,000s of people lived on the land ... fire to control the availability of plants they used ... to use fire to maintain desired habitat and natural ... Forest Service,s Pacific Southwest Station, will lead a ... Refuge during the Ecological Society of America,s 99th Annual ...
(Date:7/25/2014)... on this false-color image from the Terra satellite show the ... of wildfires in Eastern Russia. The burn scars show ... The wildfires have broken across the remote parts of ... false-color image from the MODIS instrument, it is still ... continue. Two recent image features noted below show the devastating ...
Breaking Biology News(10 mins):First national study finds trees saving lives, reducing respiratory problems 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... 2010 Country roadways can be hazardous for moose and ... elk and caribou in North America and Europe each year. ... pools that collect following pavement deicing. Because moose ... weighing up to 720 kilograms, their salt cravings can pose ...
... the Free State in South Africa (Ren Fourie and Charles ... (Rudy Jocqu) discovered very poorly known purse-web spiders of the ... new to science. The study was published in the open ... unique about purse-web spiders is that, in contrast to trapdoor ...
... have shown that a new experimental vaccine helps to ... from CSIRO,s Australian Animal Health Laboratory (AAHL) will announce ... Australian Veterinary Association conference in Adelaide today. "Our ... the infection of horses with Hendra virus," Dr Middleton ...
Cached Biology News:Of moose and men 2Vaccine protects from deadly Hendra virus 2
Form: Ready to use Applications: Immunohistology-frozen, Immunohistology-paraffin, Western Blot, ELISA...
... x W x H): 17 3/4" ... lbsCapacity: 12 slidesTime: Programmable 0 - 100 ... and hybridization steps 40 user programmable protocols ... Fixed temperature) Rapid temperature ramp-up from 37 ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Anti-Mouse Macrophages (Metallophillic), Purified (Clone MOMA-1) (rat IgG2a)...
Biology Products: